



山東威高集團醫用高分子製品股份有限公司
Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

18 September 2023

To the Independent Shareholders

Dear Sir or Madam,

**CONTINUING CONNECTED TRANSACTIONS
RENEWAL OF PURCHASE FRAMEWORK AGREEMENT
AND
RENEWAL OF LOGISTIC SUPPORT
SERVICES FRAMEWORK AGREEMENT**

We refer to the circular of the Company to the Shareholders dated 18 September 2023 (the “Circular”), of which this letter forms part. Terms defined in the Circular shall have the same meanings in this letter unless the context otherwise requires.

We have been appointed as the Independent Board Committee to consider whether the terms of the Purchase Framework Agreement (as supplemented by the Supplemental Purchase Framework Agreement) and the Logistic Support Services Framework Agreement (as supplemented by the Supplemental Logistic Support Services Framework Agreement) and the transactions contemplated thereunder, and the Proposed Annual Caps are fair and reasonable, and are in the interests of the Company and the Shareholders as a whole, and to advise the Independent Shareholders as to voting at the Third EGM.

The Independent Financial Adviser has been appointed by the Company to advise us and the Independent Shareholders in these regards. Details of the independent advice of the Independent Financial Adviser, together with the principal factors and reasons the Independent Financial Adviser has taken into consideration, are set out on pages 23 to 53 of the Circular.

We wish to draw your attention to the letter from the Board set out on pages 5 to 20 of the Circular and the letter of advice from the Independent Financial Adviser set out on pages 23 to 53 of the Circular and to the appendix to the Circular.

Having considered, among other things, the principal factors and reasons underlying the Supplemental Purchase Framework Agreement and the Supplemental Logistic Support Services Framework Agreement as well as the advice of the Independent Financial Adviser as set out in the Circular, we consider (i) the Continuing Connected Transactions under the Purchase Framework Agreement (as supplemented by the Supplemental Purchase Framework Agreement) and the Logistic Support Services Framework Agreement (as supplemented by the Supplemental Logistic Support Services Framework Agreement) are on normal commercial terms, in the ordinary and usual course of business of the Group, fair and reasonable and in the interests of the Company and the Independent Shareholders as a whole; and (ii) the Proposed Annual Caps are fair and reasonable so far as the Company and the Independent Shareholders are concerned. Accordingly, we recommend the Independent Shareholders to vote in favour of the ordinary resolutions to be proposed at the Third EGM to approve the Purchase Framework Agreement (as supplemented by the Supplemental Purchase Framework Agreement), the Logistic Support Services Framework Agreement (as supplemented by the Supplemental Logistic Support Services Framework Agreement) and the transactions contemplated thereunder and the Proposed Annual Caps.

Yours faithfully,
For and on behalf of
The Independent Board Committee of
Shandong Weigao Group Medical Polymer Company Limited



Mr. Li Guohui
Mrs. Meng Hong
Mr. Li Qiang

* for identification purposes only